Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX – Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 40,500 shares, a growth of 163.0% from the September 30th total of 15,400 shares. Based on an average trading volume of 12,300 shares, the short-interest ratio is presently 3.3 days. Currently, 0.5% of the shares of the company are sold short.
Wall Street Analysts Forecast Growth
Separately, StockNews.com started coverage on Cumberland Pharmaceuticals in a research report on Friday. They issued a “hold” rating for the company.
Get Our Latest Research Report on Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Stock Performance
Cumberland Pharmaceuticals Company Profile
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Featured Stories
- Five stocks we like better than Cumberland Pharmaceuticals
- What is Put Option Volume?
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Technology Stocks Explained: Here’s What to Know About Tech
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.